147 related articles for article (PubMed ID: 28371614)
21. Oncolytic viruses and DNA-repair machinery: overcoming chemoresistance of gliomas.
Jiang H; Alonso MM; Gomez-Manzano C; Piao Y; Fueyo J
Expert Rev Anticancer Ther; 2006 Nov; 6(11):1585-92. PubMed ID: 17134363
[TBL] [Abstract][Full Text] [Related]
22. Temozolomide: a novel oral alkylating agent.
Danson SJ; Middleton MR
Expert Rev Anticancer Ther; 2001 Jun; 1(1):13-9. PubMed ID: 12113120
[TBL] [Abstract][Full Text] [Related]
23. Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication.
Aghi M; Rabkin S; Martuza RL
J Natl Cancer Inst; 2006 Jan; 98(1):38-50. PubMed ID: 16391370
[TBL] [Abstract][Full Text] [Related]
24. Is the absolute value of O(6)-methylguanine-DNA methyltransferase gene messenger RNA a prognostic factor, and does it predict the results of treatment of glioblastoma with temozolomide?
Tanaka S; Akimoto J; Narita Y; Oka H; Tashiro T
J Neurosurg; 2014 Oct; 121(4):818-26. PubMed ID: 25105699
[TBL] [Abstract][Full Text] [Related]
25. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
Wick W; Hartmann C; Engel C; Stoffels M; Felsberg J; Stockhammer F; Sabel MC; Koeppen S; Ketter R; Meyermann R; Rapp M; Meisner C; Kortmann RD; Pietsch T; Wiestler OD; Ernemann U; Bamberg M; Reifenberger G; von Deimling A; Weller M
J Clin Oncol; 2009 Dec; 27(35):5874-80. PubMed ID: 19901110
[TBL] [Abstract][Full Text] [Related]
26. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
27. IFN-beta down-regulates the expression of DNA repair gene MGMT and sensitizes resistant glioma cells to temozolomide.
Natsume A; Ishii D; Wakabayashi T; Tsuno T; Hatano H; Mizuno M; Yoshida J
Cancer Res; 2005 Sep; 65(17):7573-9. PubMed ID: 16140920
[TBL] [Abstract][Full Text] [Related]
28. Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients.
Sartore-Bianchi A; Pietrantonio F; Amatu A; Milione M; Cassingena A; Ghezzi S; Caporale M; Berenato R; Falcomatà C; Pellegrinelli A; Bardelli A; Nichelatti M; Tosi F; De Braud F; Di Nicolantonio F; Barault L; Siena S
Eur J Cancer; 2017 Jan; 71():43-50. PubMed ID: 27997874
[TBL] [Abstract][Full Text] [Related]
29. Temozolomide and radiation in low-grade and anaplastic gliomas: temoradiation.
Schiff D
Cancer Invest; 2007 Dec; 25(8):776-84. PubMed ID: 17952745
[TBL] [Abstract][Full Text] [Related]
30. Prognostic impact of molecular phenotype in patients with recurrent anaplastic glioma treated with prolonged administration of temozolomide.
Kong DS; Kim HR; Choi YR; Seol HJ; Lee JI; Nam DH
J Clin Neurosci; 2015 Sep; 22(9):1425-9. PubMed ID: 26138051
[TBL] [Abstract][Full Text] [Related]
31. Temozolomide: a milestone in the pharmacotherapy of brain tumors.
Weller M; Steinbach JP; Wick W
Future Oncol; 2005 Dec; 1(6):747-54. PubMed ID: 16556052
[TBL] [Abstract][Full Text] [Related]
32. The role of temozolomide in the treatment of aggressive pituitary tumors.
Liu JK; Patel J; Eloy JA
J Clin Neurosci; 2015 Jun; 22(6):923-9. PubMed ID: 25772801
[TBL] [Abstract][Full Text] [Related]
33. Mechanisms and therapeutic implications of hypermutation in gliomas.
Touat M; Li YY; Boynton AN; Spurr LF; Iorgulescu JB; Bohrson CL; Cortes-Ciriano I; Birzu C; Geduldig JE; Pelton K; Lim-Fat MJ; Pal S; Ferrer-Luna R; Ramkissoon SH; Dubois F; Bellamy C; Currimjee N; Bonardi J; Qian K; Ho P; Malinowski S; Taquet L; Jones RE; Shetty A; Chow KH; Sharaf R; Pavlick D; Albacker LA; Younan N; Baldini C; Verreault M; Giry M; Guillerm E; Ammari S; Beuvon F; Mokhtari K; Alentorn A; Dehais C; Houillier C; Laigle-Donadey F; Psimaras D; Lee EQ; Nayak L; McFaline-Figueroa JR; Carpentier A; Cornu P; Capelle L; Mathon B; Barnholtz-Sloan JS; Chakravarti A; Bi WL; Chiocca EA; Fehnel KP; Alexandrescu S; Chi SN; Haas-Kogan D; Batchelor TT; Frampton GM; Alexander BM; Huang RY; Ligon AH; Coulet F; Delattre JY; Hoang-Xuan K; Meredith DM; Santagata S; Duval A; Sanson M; Cherniack AD; Wen PY; Reardon DA; Marabelle A; Park PJ; Idbaih A; Beroukhim R; Bandopadhayay P; Bielle F; Ligon KL
Nature; 2020 Apr; 580(7804):517-523. PubMed ID: 32322066
[TBL] [Abstract][Full Text] [Related]
34. Novel MSH6 mutations in treatment-naïve glioblastoma and anaplastic oligodendroglioma contribute to temozolomide resistance independently of MGMT promoter methylation.
Nguyen SA; Stechishin OD; Luchman HA; Lun XQ; Senger DL; Robbins SM; Cairncross JG; Weiss S
Clin Cancer Res; 2014 Sep; 20(18):4894-903. PubMed ID: 25078279
[TBL] [Abstract][Full Text] [Related]
35. O6-methylguanine-DNA methyltransferase-deficient phenotype in human gliomas: frequency and time to tumor progression after alkylating agent-based chemotherapy.
Silber JR; Blank A; Bobola MS; Ghatan S; Kolstoe DD; Berger MS
Clin Cancer Res; 1999 Apr; 5(4):807-14. PubMed ID: 10213216
[TBL] [Abstract][Full Text] [Related]
36. [Glioma therapy up-date].
de la Fuente BP; Dalmau J; Rosenfeld M
Neurologia; 2007 Apr; 22(3):159-69. PubMed ID: 17364254
[TBL] [Abstract][Full Text] [Related]
37. The rs16906252:C>T SNP is not associated with increased overall survival or temozolomide response in a Han-Chinese glioma cohort.
Wei KC; Chen CY; Feng LY; Huang WT; Chen CH; Hsu PW; Wang K; Hood LE; Chen LY
PLoS One; 2017; 12(6):e0178842. PubMed ID: 28575062
[TBL] [Abstract][Full Text] [Related]
38. [Predictive molecular pathological testing in the diagnosis of high-grade tumors of glial origin].
Molnár P; Méhes G
Magy Onkol; 2009 Mar; 53(1):33-8. PubMed ID: 19318324
[TBL] [Abstract][Full Text] [Related]
39. Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker.
Pietanza MC; Kadota K; Huberman K; Sima CS; Fiore JJ; Sumner DK; Travis WD; Heguy A; Ginsberg MS; Holodny AI; Chan TA; Rizvi NA; Azzoli CG; Riely GJ; Kris MG; Krug LM
Clin Cancer Res; 2012 Feb; 18(4):1138-45. PubMed ID: 22228633
[TBL] [Abstract][Full Text] [Related]
40. O6-methylguanine-DNA methyltransferase, O6-benzylguanine, and resistance to clinical alkylators in pediatric primary brain tumor cell lines.
Bobola MS; Silber JR; Ellenbogen RG; Geyer JR; Blank A; Goff RD
Clin Cancer Res; 2005 Apr; 11(7):2747-55. PubMed ID: 15814657
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
